STANDARD BIOTOOLS INC.
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
LAB$0.64+2.2%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $150,880 | $166,728 |
| Short-term investments | 107,182 | 126,146 |
| Accounts receivable, net | 35,480 | 33,608 |
| Inventory | 42,125 | 40,737 |
| Prepaid expenses and other current assets | 8,352 | 8,661 |
| Total current assets | 344,019 | 375,880 |
| Inventory, non-current | 18,281 | 18,528 |
| Property and equipment, net | 43,593 | 42,556 |
| Operating lease right-of-use asset, net | 27,422 | 28,828 |
| Other non-current assets | 6,506 | 6,301 |
| Acquired intangible assets, net | 28,057 | 28,954 |
| Goodwill | 111,719 | 111,297 |
| Total assets | $579,597 | $612,344 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $11,778 | $12,282 |
| Accrued liabilities | 21,972 | 30,739 |
| Operating lease liabilities, current | 6,334 | 6,228 |
| Deferred revenue, current | 12,763 | 13,118 |
| Deferred grant income, current | 3,389 | 3,527 |
| Total current liabilities | 56,236 | 65,894 |
| Convertible notes, non-current | 299 | 299 |
| Deferred tax liability | 1,031 | 1,081 |
| Operating lease liabilities, non-current | 24,897 | 26,469 |
| Deferred revenue, non-current | 32,548 | 32,674 |
| Deferred grant income, non-current | 6,501 | 7,243 |
| Other non-current liabilities | 3,490 | 6,962 |
| Total liabilities | 125,002 | 140,622 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.001 par value, 10,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024 | — | — |
| Common stock: $0.001 par value, 600,000 shares authorized at March 31, 2025 and December 31, 2024; 397,667 and 396,110 shares issued at March 31, 2025 and December 31, 2024, respectively; 379,087 and 377,530 shares outstanding at March 31, 2025 and December 31, 2024, respectively | 397 | 396 |
| Additional paid-in capital | 1,711,180 | 1,702,219 |
| Accumulated other comprehensive loss | 1,169 | 1,225 |
| Accumulated deficit | (1,211,684) | (1,185,651) |
| Treasury stock at cost: 18,580 shares at March 31, 2025 and December 31, 2024 | (46,467) | (46,467) |
| Total stockholders’ equity | 454,595 | 471,722 |
| Total liabilities and stockholders’ equity | $579,597 | $612,344 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.